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Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system
(CNS), in which T-cell migration into the CNS is key for pathogenesis. Patients with MS
exhibit impaired regulatory T cell populations, and both Foxp3+ Tregs and type I
regulatory T cells (Tr1) are dysfunctional. MS is a multifactorial disease and vitamin D
deficiency is associated with disease. Herein, we examined the impact of 1,25(OH)2D3 on
CD4+ T cells coactivated by either CD28 to induce polyclonal activation or by the
complement regulator CD46 to promote Tr1 differentiation. Addition of 1,25(OH)2D3
led to a differential expression of adhesion molecules on CD28- and CD46-costimulated T
cells isolated from both healthy donors or from patients with MS. 1,25(OH)2D3 favored
Tr1 motility though a Vitamin D-CD46 crosstalk highlighted by increased VDR expression
as well as increased CYP24A1 and miR-9 in CD46-costimulated T cells. Furthermore,
analysis of CD46 expression on T cells from a cohort of patients with MS supplemented by
vitamin D showed a negative correlation with the levels of circulating vitamin D. Moreover,
t-Distributed Stochastic Neighbor Embedding (t-SNE) analysis allowed the visualization
and identification of clusters increased by vitamin D supplementation, but not by placebo,
that exhibited similar adhesion phenotype to what was observed in vitro. Overall, our data
show a crosstalk between vitamin D and CD46 that allows a preferential effect of Vitamin D
on Tr1 cells, providing novel key insights into the role of an important modifiable
environmental factor in MS.
Keywords: vitamin D, multiple sclerosis, type I regulatory T cells, adhesion, CD46INTRODUCTION
Vitamin D deficiency is a growing public health problem that is proposed as a contributing factor in
several chronic inflammatory diseases. Vitamin D3 (cholecalciferol) is formed in the skin from 7-
dehydrocholesterol following exposure to the ultraviolet radiation in sunlight. It is converted by
hydroxylation in the liver to 25-hydroxyvitamin D3 (25(OH)D3) (calcidiol). This is followed by a
second hydroxylation in the kidney to 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) (calcitriol) which
is the active form of vitamin D. Vitamin D metabolism is controlled by several enzymes including
the cytochrome P450 monooxygenase 25(OH)D 1a hydroxylase (CYP27B1; 1a(OH)ase), whichorg November 2020 | Volume 11 | Article 5987271
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converts it back to an inactive form for further degradation.
Importantly, these enzymes are also active in leukocytes enabling
them to regulate the presence of 1,25(OH)2D3 in the micro-
environment (1). Indeed, 1,25(OH)2D3 has immunomodulatory
roles and exerts a direct action on T cells (2). T cell activation
induces the expression of the nuclear Vitamin D receptor (VDR),
which is required for T cell activation (3). 1,25(OH)2D3
decreases secretion of IFNg, increases IL-10 production and
generates both conventional CD25+Foxp3+ regulatory T cells
(Tregs) and IL-10-secreting Type I regulatory cells (Tr1) (4–7),
which are essential for immune homeostasis (8, 9).
Multiple sclerosis (MS) is a complex autoimmune inflammatory
disease of the central nervous system (CNS) in which genetic
predisposition and environmental factors contribute to disease
pathogenesis (10, 11). The key role of the immune system in MS
pathogenesis has been highlighted by genome-wide association
studies (12), and the efficacy of immune-targeting therapeutic
strategies, with a central role for T cells due to effector T cells
(Teffs) that recognize auto-antigens and reduced numbers or
impaired function of regulatory T cells. Both Foxp3+ Tregs and
Tr1, such as those induced by ligation of the complement regulator
CD46 (13, 14), are dysregulated in MS (15–17). While CD46
costimulation first promotes Th1 differentiation, as IL-2
accumulates, CD46 switches human T cells from a Th1 to a Tr1
phenotype, characterized by moderate IFN-g and high IL-10
secretion (13, 14). T cell activation induces secretion of C3b, a
ligand for CD46, resulting into autocrine activation of the T cells
(14). CD46 induction of the Tr1 phenotype is dysregulated in MS
and other chronic inflammatory diseases, as CD46-costimulated T
cells in these patients secrete less IL-10 but normal levels of IFN-g
(14, 16, 18–21). Patients with relapsing-remitting MS have lower
levels of circulating vitamin D than controls (22, 23). Treatment
with 1,25(OH)2D3 suppresses the development and progression of
experimental autoimmune encephalomyelitis (EAE), a murine
model of MS (5, 24). In MS, Vitamin D supplementation is safe
and has been variably associated with improvement of disease (25,
26) andwith amodulation of T cell responses (27–29). In vitro, 1,25
(OH)2D3 promotes CD46 shedding and the switch to Tr1
differentiation, suggesting that it acts in part through its effects on
CD46 (7). Furthermore, 1,25(OH)2D3 can restore the correct ratio
of IL-10:IFNg produced by CD46-costimulated T cells from
patients with MS (7).
Immune cell trafficking across the blood-brain-barrier (BBB)
is a multi-step process that involves the sequential interaction of
specific cellular adhesion and signaling molecules, such as the
integrin VLA-4 (a4b1, CD49d/CD29), LFA-1 (aLb2, CD11a/
CD18) and other cellular adhesion molecules such as CD226,
CD166, CD146, CD6, and CD99 (30). Recruitment of T cells into
the CNS is indeed crucial for the pathology of MS and molecules
controlling T cell migration represent key targets for therapy.
However, blocking immune cell trafficking is associated with
potentially fatal side-effects including progressive multifocal
leukoencephalopathy due to limitation of the CNS immune
surveillance (31). Therefore, it is important to determine
whether distinct adhesion molecules drive the migration ofFrontiers in Immunology | www.frontiersin.org 2effector T cells and/or regulatory T cells into the CNS, to
preferentially target migration of pathogenic T cells.
In this study, we analyze the role of 1,25(OH)2D3 on
polyclonally activated T cells or Tr1 differentiated T cells, in
the context of T cell migration in MS. Overall, our data suggest
that Vitamin D favors response to CD46-induced Tr1 cells
through increased VDR expression and allowing a better
response to Vitamin D that promotes Tr1 cells. This represents
a key mechanism to promote immuno-modulation in chronic
inflammatory diseases, including MS.MATERIALS AND METHODS
Cell Purification and Activation
Peripheral Blood Mononuclear Cel (PBMCl) were isolated from
blood obtained after informed consent of patients in the relapsing-
remitting stage (RRMS, see patient description in Table 1, ethical
approval SR258) or from age and sex-matched healthy donors
(ethical approval AMREC 115-HV-013), and samples were
obtained after informed consent according to the Declaration of
Helsinki. Purified CD4+ T cells (StemCell, Grenoble, France)
(Supplementary Figure S1) were activated for four days with
pre-coated anti-CD3 (OKT3, 5µg/ml)/anti-CD46 (MC120.6, 10
µg/ml) or anti-CD3/anti-CD28 (CD28.2, Biolegend, 5 µg/ml), and
10U/mlof rhIL-2 (CambridgeBioscience,Cambridge,UK) (13).At
the beginning of the culture, cellswere treatedwith10-7M1,25(OH)
2D3 (Sigma, Gillingham, UK), a dose previously reported to
promote IL-10-producing Tr1 cells (6, 32, 33) or the vehicle
control, ethanol.
Patients Supplemented by Vitamin D
Frozen PBMCs from RRMS patients from a former study (34)
were obtained and subjected to flow cytometry analysis. Briefly,TABLE 1 | Multiple Sclerosis (MS) patient characteristics.
Patient Age Gender EDSS Treatment
MS1 n/a M 1 None
MS2 43 F 1 Dimethyl fumarate
MS4 25 M 1 Dimethyl fumarate
MS5 49 F 1.5 None
MS6 33 F 1 None
MS7 41 F 2 Beta Interferon
MS8 39 M 2 Dimethyl fumarate
MS10 32 F 1 Beta Interferon
MS11 46 F 0 Dimethyl fumarate
MS12 55 F 2 Dimethyl fumarate
MS13 33 F 1 Dimethyl fumarate
MS14 39 F 0 Dimethyl fumarate
MS15 31 F 0 Dimethyl fumarate
MS16 37 F 1 Dimethyl fumarate
MS17 53 M 2 Dimethyl fumarate
MS18 49 F 2 Dimethyl fumarate
MS19 32 M 1 Dimethyl fumarate
MS20 44 F 2 Dimethyl fumarate
MS21 21 M n/a Dimethyl fumarate
MS22 36 M 1 Dimethyl fumarate
MS23 57 F 7 NoneNovember 2020 | Volume 11 | Article 598727
Killick et al. Vitamin D Favors Tr1 ResponseRRMS patients with relapsing-remitting MS received vitamin D3
supplements (4,000 IU/day) or placebo during 16 weeks and
flow cytometry analyses were performed before and
after supplementation.
Flow Cytometry
After T cell activation, T cells were stained with directly labeled
antibodies (or isotype controls) as follows: CD46 (FITC, clone:
MEM-258, Biolegend), CD11a (PE, clone HI111, Biolegend),
CD69 (FITC, clone FN50, Biolegend), CD99 (PE, clone 3B2/
TA8, Biolegend), CD29 (PE, clone: TS2/16, Biolegend), CD49d
(APC, clone: 9F10, Biolegend), CXCR3 (PE human, Miltenyi
Biotech), CD226 (APC, clone 11A8, Biolegend), CD146 (APC,
clone P1H12, Biolegend), CD166 (PE, clone 3A6, Biolegend),
TIGIT (APC, clone: A15 15 36, Biolegend). Cells were analyzed
using a FACSCalibur or a 5 laser LST Fortessa (BD Biosciences).
A live-dead marker (LIVE/DEAD™ Fixable Far Red Dead Cell
Stain, Thermofisher) was added to the cells to exclude dead cells.
The delta geometric mean is shown (MFI staining – MFI
isotype). Representative staining are shown in Supplementary
Figure S1. For the cohort of patients supplemented with vitamin
D, PBMCs were analyzed with a panel of antibodies consisting of
CD3-AF700, CD4-FITC, CD25-BV605, CD127-BV421,
CD45RA-BV510, Foxp3-PE, CD46-PE/cy7, CD226-PE-dazzle
594, CD146-APC, CD162-BV711, CD6-BV785. Viable cells
were selected using the NIR-ZOMBIE APC-Cy7 (Biolegend)
(Supplementary Figure S1C). Cells were analyzed using a
Fortessa (BD Biosciences) and analysis was done using FlowJo
and t-SNE clustering.
Analysis of Flow Cytometry Data
With t-SNE and Phenograph
Data were first analyzed using FlowJo with FlowAI that cleans
unwanted events by evaluating three different properties (abrupt
changes in the flow rate, instability of signal acquisition and outliers
in the lower limit and margin events in the upper limit of the
dynamic range) (35). The number of live CD3+CD4+ T was
reduced in order to normalize the number of events from each
file to the concatenated total. Samples were randomly downsampled
to 20,000 events per sample for ex vivo PBMCs (10,000 events per
sample for activated cells). The concatenated population contained
a total of 360,000 cells for ex vivo PBMCs (140,000 per sample for
activated cells. A t-Distributed Stochastic Neighbor Embedding
(tSNE) was then run on the concatenated file to allow the
visualization of complex multi-dimensional data in fewer
dimensions. Events with a similar multidimensional expression
pattern group together within the dimensionally reduced data
space. CD3, CD4 and Viability Dye were removed from the t-
SNE and Phenograph analysis. In order to choose the analysis
parameters for the t-SNE and Phenograph analysis, the data were
run with increasing perplexity (from 10 to 10 starting at 30 as the
default value) for t-SNE and increasing k value (from 5 to 5, starting
at 30) for Phenograph (36). From a perplexity of 80 and above, the
clustering did not significantly change anymore.We therefore chose
100 and 50 for the k-value (reaching a plateau). Opt-SNE, an
automated toolkit for t-SNE parameter selection (37) was run withFrontiers in Immunology | www.frontiersin.org 3the following parameters: perplexity = 100 (the number of nearest
neighbors), iteration = 1000 (maximum number of iterations) and
Eta = 44,099 (Learning rate). In each figure, all samples were derived
from the same t-SNE run. Phenograph was also run on the
concatenated files to determine phenotypic similarities between
cells according to k-nearest neighbors (k=50) and automatically
identify clusters (38).
Chemotaxis Assay
The ability of activated CD4+ T cells to migrate toward CXCL11
was monitored by a chemotaxis assay using Transwell inserts
(6.5 mm insert, 3 mm filter, Costar). 600 ml/well RPMI or CXCL11
(100 ng/ml, Recombinant Human CXCL11 (ITAC), carrier-free,
Biolegend) was added to the lower chambers. Activated CD4+ T
cells were resuspended in fresh medium (1 million/ml) and 100 ml
was added to the upper chamber of the Transwell inserts, and
incubated at 37°C for 3.5 hrs. To evaluate chemotaxis, cells in the
bottom chamber were then analyzed by flow cytometry for 1 min
to evaluate the number of cells present. Dunn chamber chemotaxis
was performed with CD3/CD46-activated T cells allowed to
migrate in a gradient of 0-100nM nM CXCL11. Cells were
monitored in a temperature-controlled chamber for 30 min by
time-lapse imaging using an inverted RMDIB microscope (Leica)
equipped with an Orca camera (Hamamatsu) that was controlled
by Micromanager image acquisition software (Fiji). The paths of
individual cells were tracked using the manual tracking plug-in
into ImageJ and tracks analyzed using the chemotaxis tool plug-in
into ImageJ (Ibidi).
Quantification of mRNA and
miRNA by qPCR
Subsequent to T cell activation, the T cells were harvested, lysed in
TRIzol reagent (Qiagen) and the total RNA isolated using the
miRNeasy mini kit (Qiagen) as directed by the manufacturer. The
quantity and purity of the extracted RNA was determined using a
Nanodrop spectrophotometer and cDNA generated using the
QuantiTect reverse transcription kit (Qiagen). Relative mRNA
e x p r e s s i o n o f C Y P 2 7 B 1 ( F o r w a r d p r i m e r :
CCAGACAGCACTCCACTCAG, Reverse primer: ACAGAGT
GACCAGCGTATTT), CYP24A1 (Forward primer: GATTTTCC
GCATGAAGTTGGGT, Reverse primer: CCTTCCACGGTTTG
ATCTCCA) and VDR (Forward primer: GTGGACATCGGCA
TGATGAAG, Reverse primer: GGTCGTAGGTCTTATGGTGGG)
using a Roche Lightcycler with PowerUp SYBR green mastermix
(ThermoFisher). The ribosomal proteinRPL13A, (Forwardprimer:
ACCGTCTCAAGGTGTTTGACG, Reve r s e Pr imer :
GTACTTCCAGCCAACCTCGTG) was used as an endogenous
control (1). Expression of miR-9 and RNU-44 was assessed using
Taqman miRNA assays (Applied Biosystems). Results were
analyzed using the (2-DDCt) method with normalization against
RPL13a and RNU44 expression for mRNA and miR, respectively.
Results are expressed as fold change relative to unstimulated cells.
Statistics
The groups were analyzed using Graphpad Prism software. All
data are represented as mean ± standard error of the meanNovember 2020 | Volume 11 | Article 598727
Killick et al. Vitamin D Favors Tr1 Response(SEM), and were analyzed using the Wilcoxon test when
assessing paired samples, or ANOVA with appropriate post hoc
analysis for multiple comparisons. A non-parametric Mann-
Whitney test or Kruskall-Wallis test was used to compare
healthy T cells and MS T cells. Regression analysis was used to
test for correlations between vitamin D concentrations and
CD46 expression. P-values were considered significant as
follows: *: p<0.05 to 0.01, **: 0.001 to 0.01, ***: 0.0001 to
0.001, and ****: < 0.0001.RESULTS
1,25(OH)2D3 Differentially Modulates
Surface Expression of Adhesion Molecules
Depending on the Activation Pathway
Purified human CD4+ T cells from healthy donors were
activated in the presence or absence of 1,25(OH)2D3 by either
CD3/CD28 to assess polyclonally activated effector T cells orFrontiers in Immunology | www.frontiersin.org 4were costimulated with the complement regulator CD46 to
induce Tr1-like cells (13, 14) (Supplementary Figure S2).
Expression of the integrins CD49d (the a chain of VLA-4, a4),
CD29 (the b chain of VLA-4, b1) and CD11a (the a chain of
LFA-1, aL), known to be involved in the regulation of T cell
trafficking to the CNS, was determined. The expression of CD46
and CD69 was used to assess activation. As previously reported
(7), the addition of 1,25(OH)2D3 promoted CD46 shedding
upon its ligation (Figure 1A) that is required for Tr1
differentiation (39, 40). The two costimulation pathways
induced similar expression of the activation marker CD69, and
this was strongly increased by the addition of 1,25(OH)2D3. In
contrast, 1,25(OH)2D3 inhibited T-cell activation dependent
upregulation of CD49d, and significantly decreased CD29 on
CD28- but not on CD46-coactivated T cells, and had no
significant effect on CD11a expression (Figure 1A). To better
visualize the modulation of expression, the difference in the levels
of CD49d, CD29 and CD11a after activation with CD46 or CD28
costimulation compared to their basal expression inA
B
FIGURE 1 | 1,25(OH)2D3 differentially modulates integrin surface expression on activated T cells depending on their activation pathway. (A) Human CD4+ T cells
were left unstimulated (US) or were activated with anti-CD3 and anti-CD28 or anti-CD46 as indicated, in the presence or absence of 1,25(OH)2D3 (VitD). After 4
days, expression of CD46, CD69, CD49d, CD29, and CD11a was assessed by flow cytometry (mean ± SEM, n= 24, one way ANOVA with Holm-Sidak’s multiple
comparisons post hoc test). (B) The change in expression of CD49d, CD29, and CD11a upon activation compared to expression in unstimulated T cells was
calculated (mean ± SEM, n= 22, Friedman test with Dunn’s multiple comparisons test). *: p<0.05 to 0.01, **: 0.001 to 0.01, ***: 0.0001 to 0.001, and ****: < 0.0001.November 2020 | Volume 11 | Article 598727
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previously reported that 1,25(OH)2D3 increased expression of
the skin-homing chemokine receptor CCR10, and decreased
expression of the gut-homing trafficking molecules a4b7-
integrin and CCR9 (41). In agreement, we also observed that
Vitamin D reduced b7-integrin expression on CD28-coactivated
T cells (Supplementary Figure S3A). In contrast, we found that
1,25(OH)2D3 significantly increased expression of CCR9, but
not CCR10, following both costimulation pathways
(Supplementary Figure S3B), and we did not detect a
significantly increased b7-integrin expression after CD46-
costimulation as previously reported (42).
We next assessed the effect of 1,25(OH)2D3 on a panel of
activation and cellular adhesion molecules that had been
previously identified as playing a role in T cell activation and/
or migration to the CNS (43–46). First, we observed that, in the
absence of 1,25(OH)2D3, CD28 and CD46 costimulations led to
a differential modulation of these surface receptors (Figure 2).
CD46 notably promoted expression of CD226/DNAM-1,
CD146/MCAM, and CD166/ALCAM but reduced CD99.
Second, 1,25(OH)2D3 had marked effects by increasing CD6,Frontiers in Immunology | www.frontiersin.org 5CD226 as well as CD99 expression and decreasing CD146 and
CD166 expression. Except for CD166, 1,25(OH)2D3-treated
CD46-costimulated T cells expressed higher levels of cellular
adhesion molecules compared with CD28-costimulated T cells
(Figure 2).
The effect of 1,25(OH)2D3 on T cells isolated from patients
with relapsing-remitting MS (RRMS) was next examined
(Supplementary Figure S4). We calculated the difference in
expression of adhesion molecules upon addition of 1,25(OH)
2D3 (Figure 3). Similar effects of 1,25(OH)2D3 were observed
for healthy donors and RRMS patients, although the increase in
CD6 and CD226 observed with addition of 1,25(OH)2D3 was
reduced in CD46-costimulated MS cells; this also holds for the
decrease in CD49d expression. These changes seemed to be
independent of disease-modifying treatments (Supplementary
Figure S5).
Overall, these data demonstrate a distinct modulation of cell
adhesion molecules controlling migration by 1,25(OH)2D3 on
CD28- and CD46-costimulated T cells. Similar trends were
observed on T cells isolated from healthy donors and patients
with RRMS, although CD46 costimulation of MS T cells revealedFIGURE 2 | 1,25(OH)2D3 differentially modulates the expression of cellular adhesion molecules on activated T cells depending on their activation pathway. Human
CD4+ T cells were left unstimulated (US) or were activated with anti-CD3 and anti-CD28 or anti-CD46 as indicated, in the presence or absence of 1,25(OH)2D3
(VitD). After 4 days, expression of CD6, CD226, CD146, CD166, and CD99 was assessed by flow cytometry (mean ± SEM, n= 24 (n= 15 for CD99), one way
ANOVA with Holm-Sidak’s multiple comparisons post hoc test). *: p<0.05 to 0.01, **: 0.001 to 0.01, ***: 0.0001 to 0.001, and ****: < 0.0001.November 2020 | Volume 11 | Article 598727
Killick et al. Vitamin D Favors Tr1 ResponseFIGURE 3 | 1,25(OH)2D3 exerts similar effects on the phenotype of activated multiple sclerosis (MS) T cells. CD4+ T cells isolated from the cohort of healthy
controls (HC) (shown in Figures 1 and 2) or patients with relapsing-remitting stage (RRMS) (n=20) were activated with anti-CD3 and anti-CD28 or anti-CD46 as
indicated, in the presence or absence of 1,25(OH)2D3 (VitD). The difference in expression of CD49d, CD29, CD11a, CD99, CD6, CD226, CD146, and CD166
induced by 1,25(OH)2D3 is plotted, Kruskall-Wallis test. *: p<0.05 to 0.01 and **: 0.001 to 0.01.Frontiers in Immunology | www.frontiersin.org November 2020 | Volume 11 | Article 5987276
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in these patients (16, 18).
1,25(OH)2D3 Favors Chemotaxis of CD46-
Mediated Tr1 Cells Toward CXCL11
Through a CD46-Vitamin D Crosstalk
Chemokine receptors dictate chemotaxis and migration of
activated T cells. Notably CXCR3 is implicated in regulating T
cell migration in MS and 1,25(OH)2D3 reduces CXCR3
expression in EAE (47). We assessed chemotaxis of activated T
cells (upper chambers) toward the CXCR3 ligand CXCL11
(lower chambers). Addition of CXCL11 increased migration of
both CD28- and CD46-coactivated T cells (Figure 4A, left
panel). 1,25(OH)2D3 enhanced CXCL11-mediated chemotaxis,
and it favored migration of CD46-costimulated cells compared
with CD28-activated T cells (~3 fold increase) (Figure 4A, right
panel). The effect of 1,25(OH)2D3 on increasing Tr1-like cell
motility was confirmed by assessing velocity and distance
traveled using Dunn chambers (Figures 4B, C).
The increased motility induced by 1,25(OH)2D3 was not due
to increased CXCR3 expression on activated T cells
(Supplementary Figure S6). The biological functions of 1,25
(OH)2D3 are mediated through the VDR. Moreover, the amount
of 1,25(OH)2D3 available is regulated by CYP27B1 and
CYP24A1. To explain the preferential effect of vitamin D on
CD46-costimulated cells compared with CD28-activated cells,
the levels of expression of VDR, CYP27B1 and CYP24A1 mRNA
in activated T cells were assessed, with and without the addition
of 1,25(OH)2D3 (Figure 5). We also examined expression of theFrontiers in Immunology | www.frontiersin.org 7miRNA miR-9 that regulates VDR expression (48). Differences
in their expression were found depending on the costimulatory
signals received by the T cells. Increased VDR expression was
detected upon T cell activation confirming previous reports (3),
but CD46-costimulation doubled VDR expression when
compared with CD28-costimulation, and expression was
further increased by addition of 1,25(OH)2D3. Expression of
miR-9 was increased following CD46-costimulation, and
significantly augmented in the presence of 1,25(OH)2D3.
CYP27B1 was not significantly increased by CD46
costimulation compared with CD28 and was not modulated by
1,25(OH)2D3, but adding 1,25(OH)2D3 led to a large increase in
CYP24A1 in CD46-costimulated T cells, indicating that the
increased VDR expression is functional. As 1,25(OH)2D3
promotes the CD46-mediated switch from pro-inflammatory
Th1 to regulatory Tr1 (7, 14), these data indicate interplay
between the CD46 and Vitamin D pathways, favoring an effect
of 1,25(OH)2D3 on Tr1 cells.
Vitamin D Supplementation Modulates the
Expression of Adhesion Molecules on
CD4+ T Cells in Patients With MS In Vivo
In order to assess whether Vitamin D was able to modulate
expression of adhesion molecules in humans in vivo, we next
analyzed samples from a cohort of patients with RRMS
supplemented by vitamin D3 (or placebo) previously reported
(34). Within PBMCs, CD3+CD4+ T cells were analyzed for
CD46, CD226, CD6, CD146, CD162/PSGL1, as well as Treg
markers (Foxp3, CD25, CD127, CD45RA). Significant increasesA
B
C
FIGURE 4 | 1,25(OH)2D3 favors migration of CD46-activated T cells. (A) Human CD4+ T cells were activated as indicated and chemotaxis to CXCL11 assessed by
transwells after 3.5 hrs. The left panel shows the increased chemotaxis after normalization to migration in the absence of CXCL11 (n=10, mean ± SEM), and the right
panel the numbers of cell migrated when the cells were activated in the presence or absence of 1,25(OH)2D3 (n=6, mean ± SEM). (B, C) CD46-costimulated T cells
activated in the presence or absence of 1,25(OH)2D3 were added to Dunn chambers with CXCL11 and time-lapsed every 30 s for 30 min. Analysis of the cell
movements were performed using the chemotaxis plugin from Ibidi into imageJ. *: p<0.05 to 0.01 and ***: 0.0001 to 0.001.November 2020 | Volume 11 | Article 598727
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supplementation (Figure 6A). We first analyzed the correlation
between the concentration of circulating vitamin D and CD46
expression at the surface of T cells. A significant negative
correlation was observed for CD46 expression on CD4+ T cells
(Figure 6B). Similar trends were observed when the patients
were segregated according to vitamin D supplementation
(placebo with open circles, vitamin D with closed symbols,
untreated patients depicted as red dots). Expression of the
adhesion molecules was determined using unsupervised t-SNE
analysis and phenograph clustering that allowed the
identification of 24 clusters within the CD3+CD4+ population
(Figures 6C, D, Supplementary Figure S7). We selected clusters
for which a modulation of the proportion/cell counts was
differentially observed after vitamin D treatment or placebo.
The clusters 7, 16, and 24 were increased with VitD and/or
decreased with placebo (Figure 7A). Among these, the cluster 24
reproduced the effects observed in vitro when activated by CD46,
with reduced CD46 expression associated with an increased
expression of CD6 and CD226, and a decreased expression of
CD146 (Figure 7B). Interestingly, a strong increase in CD162
was also detected in this cluster. We confirmed the regulation of
CD162 in vitro by CD46 stimulation in the presence of vitamin D
(Supplementary Figure S8). Reduced CD25 expression was
detected on the clusters 7 and 16. In contrast, the cluster 9,
which is increased in the placebo group but stable with vitamin
D, expressed increased CD25. While an increase of CD6 wasFrontiers in Immunology | www.frontiersin.org 8observed for the clusters 7, 16, and 24, the upregulation of CD226
was only observed in the clusters 24 and 7, while cells represented
in the cluster 16 exhibited a strong downregulation of CD226
expression. This suggests that vitamin D supplementation exerts
different effects on CD226 depending on the T cell subsets.
Overall, the data show that vitamin D supplementation affects
CD46 expression and modulates the adhesion molecules on
circulating T cells, with some T cell clusters resembling the
phenotype observed after CD46 costimulation in vitro. The
analysis also allowed the identification of 2 clusters (4 and 18)
that corresponded to Tregs (Foxp3+CD25+CD127lo)
(Supplementary Figure S9). Interestingly, the cluster 4
expressed very high levels of CD146 and increased CD46
expression. However, no significant differences were observed
between the placebo and vitamin D supplemented groups as
similar increased proportions and cell numbers were detected for
both groups (Supplementary Figure S9).
Vitamin D Supplementation Modulates the
Profile of Adhesion Molecules Upon In
Vitro T Cell Activation
We next determined whether vitamin D supplementation could
modulate the profile of cell adhesion molecules after T cell
activation. We compared the phenotype of the CD3+CD4+ T
cells after costimulating the PBMCs in vitro with CD28 or CD46.
The t-SNE analysis showed, as expected, different clustering
depending on the costimulation pathway (Figures 8A, B).FIGURE 5 | Crosstalk between the CD46 and vitamin D pathways. Human CD4+ T cells were activated as indicated and expression of VDR, miR-9, CYP27B1, and
CYP24A1 was quantified by qPCR after 4 days. Relative quantification was calculated according to the expression of the house keeping gene (DCt) and the fold
change compared to unstimulated samples (2-DDCt) was calculated. Analysis was performed using one way Anova with Sidak’s multiple comparisons test. *: p<0.05
to 0.01, **: 0.001 to 0.01, ***: 0.0001 to 0.001, and ****: < 0.0001.November 2020 | Volume 11 | Article 598727
Killick et al. Vitamin D Favors Tr1 ResponseInterestingly, changes in the clustering were mainly observed
after vitamin D supplementation upon CD46 costimulation with
minimal changes observed after CD28 coactivation. The
phenograph analysis identified 19 clusters, with different
proportions depending on the costimulation pathways (Figure
8C, Supplementary Figure 10). We highlighted the clusters for
which an increased or decreased proportion was detected after
vitamin D supplementation and not placebo (Figure 8D).
Analysis of their phenotype shows that most of the clusters
that were increased by vitamin D supplementation had lower
CD25 expression and increased CD162 levels, with variable levels
of CD46, CD226, and CD6 (Figure 9A). In contrast, the clusters
decreased by vitamin D supplementation exhibited increased
CD25 expression and lower CD46 expression with minimal
changes in the adhesion molecules (Figure 9B). These data
show that vitamin D supplementation also affects the profile of
T cells upon their reactivation.Frontiers in Immunology | www.frontiersin.org 9DISCUSSION
In this study, we highlight a key role of 1,25(OH)2D3, one of the
most prevalent modifiable environmental factors in MS, in the
regulation of inflammation by demonstrating its role in
differentially modulating the expression of adhesion molecules
involved in the migration of T cells to the CNS, depending on
their activation pathways (Figure 10). Vitamin D decreases
CD49d on both CD46- and CD28-costimulated T cells, but it
only reduces CD29 in CD28-activated T cells, hence it may still
allow migration of Tr1 cells through residual VLA-4 or other b1
integrins present at the surface of these cells. Of note, the analysis
of the previously reported differentially expressed genes after
1,25(OH)2D3-treatment of EAE in the rat (49) shows decreased
expression of itga4 (coding for CD49d), itgb1 (CD29) and mcam
(CD146), suggesting, at least in part, a role of vitamin D at the
transcription level. 1,25(OH)2D3 has been reported to induce aA C
B
D
FIGURE 6 | Vitamin D supplementation modulates the phenotype of T cells in patients with multiple sclerosis (MS) in vivo. (A) 25(OH)D levels in serum before and
after a 16-week treatment with vitamin D or placebo (PCB) in a cohort of patients with MS (11 IFNb-treated, 3 untreated, red dots). (B) Correlation between the
expression of CD46 on circulating CD3+CD4+ T cells and vitamin D concentration. Placebo: open circles, vitamin D: closed symbols, untreated patients depicted as
red dots. (C) t-SNE was run on the concatenate file of 360,000 cells (perplexity = 100, iteration = 1000, Eta= 44,099). Phenograph was also run to identify clusters
(K=50) in the CD3+CD4+ T cells from five patients supplemented with vitamin D and four placebo (all IFNb treated). (D) Cell counts and percentage of the 24
clusters identified by PhenoGraph (in C) in the vitamin D and placebo groups before and after treatment. Boxes identified the clusters for which a differential
modulation was observed with vitamin D and placebo.November 2020 | Volume 11 | Article 598727
Killick et al. Vitamin D Favors Tr1 Responseskin–homing phenotype in T cells by increasing expression of
the skin-homing chemokine receptor CCR10, and decreasing
expression of the gut-homing a4b7 integrin and CCR9 (41).
While we detected a decrease in b7-integrin expression, we also
observed a significant increase in CCR9 with addition of 1,25
(OH)2D3. In the present study, we used CD4+ T cells without
IL-12 stimulation, whereas the previous study (41) used
predominantly CD8+ T cells that had been activated in the
presence of IL-12, with minimal effects on CD4+ T cells unless
these were pre-activated.
Vitamin D also strongly modulated the expression of several
adhesion molecules known to control T cell migration to the
CNS. Addition of 1,25(OH)2D3 in vitro increased expression of
both CD6 and CD226, while it decreased expression of CD166
and of CD146 especially on CD46-costimulated T cells. CD146
expression is increased on T cells from Natalizumab (anti-
integrin a4)-treated patients and favors Th17 migration (46,
50). The large reduction in CD146 expression observed followingFrontiers in Immunology | www.frontiersin.org 10Vitamin D treatment would be consistent with a reduction in
Th17 recruitment to the CNS. CD6 regulates T cell activation
and polymorphisms have been identified in MS (45).
Intriguingly, 1,25(OH)2D3 increased CD6 expression but
decreased its ligand, CD166/ALCAM. It would therefore be
interesting to determine the role of vitamin D on the
expression of CD318, a second ligand for CD6 recently
identified (51).
CD226 is expressed by Th1 and Th17 cells and its blockade
ameliorates the course of EAE (52, 53). However, the role of
CD226 in Tregs is controversial. Although CD226 upregulation
has been associated with reduced suppressive activity (54), the
level of CD226 expression in Tregs has been correlated with their
increased suppressive activity, with MS Tregs expressing lower
levels of CD226 (44). Furthermore, CD226 is also a marker of
Tr1 (55) suggesting that it plays a role in Tr1 function. Indeed,
1,25(OH)2D3, which induces CD226 on CD46-costimulated T
cells, promotes CD46-mediated Tr1 suppression (7). In EAE,A
B
FIGURE 7 | Vitamin D supplementation modulates the expression of adhesion molecules on CD4+ T cells in patients with multiple sclerosis (MS). (A) Percentage
and (B) phenotype of the clusters increased after vitamin D supplementation (clusters 7 and 16), decreased by placebo (clusters 16 and 24) or increased by placebo
but stable with vitamin D (cluster 9). The phenotype represented is from the Vitamin D after group and is representative of the four different groups as they represent
the phenotype of the cells clustered together.November 2020 | Volume 11 | Article 598727
Killick et al. Vitamin D Favors Tr1 Responseligation of CD226 has also been shown to ameliorate EAE with
an increased IL-10 production (56). Furthermore, we observed
that CD46 costimulation repressed TIGIT expression that was
induced by both CD3 and CD3/CD28 st imulat ion
(Supplementary Figure S11). TIGIT is an inhibitory co-
receptor that shares CD226 ligands. Therefore, 1,25(OH)2D3-
treated CD46-induced Tr1 will positively respond to
CD226 ligands.
1,25(OH)2D3 also induced expression of CD99 on CD46-
costimulated T cells. CD99 promotes T cell diapedesis across a
human BBB in vitro and anti-CD99 ameliorates EAE and
reduces T cell infiltration (57). Our data suggest that CD99
may however also promote migration of Tr1 cells to the CNS.
Collectively, our in vitro data suggest that the modulation of
adhesion molecules by 1,25(OH)2D3 favors migration of Tr1
cells compared with effector T cells. Indeed, 1,25(OH)2D3
increased motility of CD46-costimulated T cells in response to
CXCL11, compared with CD28-activated T cells, supporting the
previously reported notion that CXCL11 promotes migration of
regulatory T cell subsets (58). CD46-costimulated T cells hadFrontiers in Immunology | www.frontiersin.org 11increased VDR expression, which may explain the preferential
effect of Vitamin D on these cells. Furthermore, 1,25(OH)2D3
dramatically increased miR-9 in CD46-costimulated T cells. As
miR-9 targets VDR (48), we propose that the induction of miR-9
may act as a negative feedback loop to limit the effects induced by
Vitamin D, which is also supported by the large induction of
CYP24A1 that reduces the amount of available active vitamin D.
Together, these data highlight the crosstalk between the Vitamin
D and CD46 pathways, favoring the role of vitamin D in Tr1
cells. This is supported by the previous findings that vitamin D
promotes IL-10-producing T cells, both in vitro and in humans
(6, 32), and the CD46-mediated switch from Th1 to Tr1 and
CD46 cleavage on activated T cells (7). This is further sustained
by the negative correlation we detected between CD46
expression and circulating vitamin D levels in the cohort of
patients supplemented by vitamin D.
Our ex vivo findings using the cohort of patients
supplemented with vitamin D support an effect of vitamin D
in the modulation of T cells that may be relevant to disease




FIGURE 8 | Vitamin D supplementation modulates the phenotype of T cells in patients with multiple sclerosis (MS) after in vitro activation. (A) t-SNE representation
and (B) intensity of staining of CD46, CD25, CD162, CD45RA, CD127, CD6, Foxp3, and CD226 in CD3+CD4+ T cell clusters after CD28 or CD46 costimulation of
PMBCs from patients with MS supplemented by vitamin D or placebo (n=3 and n=4, respectively). (C) visualization of clusters identified by Phenograph on t-SNE-
map analysis of the CD3+CD4+ T cells. (D) Percentage of the 19 clusters identified by PhenoGraph in the vitamin D and placebo groups before and after treatment.
Clusters increased (green boxes) or decreased (blue boxes) after vitamin D supplementation are indicated.November 2020 | Volume 11 | Article 598727
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Killick et al. Vitamin D Favors Tr1 Responsecluster of T cells that was decreased in the placebo group but
maintained/increased after vitamin D supplementation, with
lower CD46 expression but increased expression of adhesion
molecules, including CD162L/PSGL1, and reduced CD146,
thereby reflecting the changes observed in our in vitro
activation conditions. This is suggestive of the activation of the
CD46 pathway by vitamin D in vivo in these patients. However,
vitamin D supplementation exerted different effects on CD226
depending on the cluster. This suggests that vitamin D will
differently regulate CD226 expression depending on the T cell
subsets. This may partly explain the controversial studies relating
to the role of CD226 in the control of the immune response.
Furthermore, the data obtained after in vitro activation suggest
that the levels of circulating vitamin D regulate the reactivation
of the T cells, modifying their phenotype in patients
supplemented by vitamin D. Interestingly, the cluster 9, which
is increased in the placebo group but stable with vitamin D in ex
vivo T cells, has increased CD25 expression, which is similar to
what we observed after in vitro reactivation of the cells. Of note,
most of the patients enrolled in the vitamin D supplementation
trial had almost normal vitamin D levels, and it is possible that
greater changes may have been observed after supplementation
with vitamin D in deficient patients. The analysis performed after
in vitro T cell activation shows a different clustering of the cells in
patients supplemented by vitamin D after CD46 costimulation,
and much less so after CD28 costimulation (Figure 8A). These
data show that vitamin D supplementation modulates the
response of T cells following subsequent T cell activation (at
least in vitro) and further support the concept that Vitamin D
favors response to CD46 costimulation.
Altogether, our data provide novel key insights into the
immunomodulatory role of vitamin D by exerting differential
regulation of adhesion molecules on T cells, depending on their
activation pathways, and suggesting that it favors the migratory
ability of regulatory T cells to the CNS. This supports a beneficial
role of this modifiable factor in MS.Frontiers in Immunology | www.frontiersin.org 13DATA AVAILABILITY STATEMENT
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SUPPLEMENTARY FIGURE 1 | Profile of adhesion molecules on activated CD4+
T cells. (A) Human CD4+ T cells obtained from blood were purified from PBMCs using
the StemCell negative CD4+ isolation kit and were activated with anti-CD3 and anti-
CD28 or anti-CD46 as indicated, in the presence or absence of 1,25(OH)2D3. (B) After
4 days of culture, cells were analyzed by flow cytometry for a panel of markers, as
indicated. (C) Frozen PBMCs from MS patients supplemented with vitamin D or
placebo were thawed and analyzed by flow cytometry for a panel of markers on CD4.
The gating strategy is shown.
SUPPLEMENTARY FIGURE 2 | 1,25(OH)2D3 promotes the Th1-Tr1 switch in
human CD4+ T cells. Human CD4+ T cells were activated with anti-CD3 and anti-
CD28 or anti-CD46 as indicated, in the presence or absence of 1,25(OH)2D3. (A)
Concentrations of IL-10 and IFNg secreted were measured by ELISA. The IL-10/
IFNg ratio is shown. One way Anova with Sidak’s multiple comparisons test. (B)
IFNg and IL-10 secretion by CD46-costimulated T cells was assessed by secretion
assay (Miltenyi).
SUPPLEMENTARY FIGURE 3 | 1,25(OH)2D3 differentially modulates
expression of b7 integrin depending on the activation pathway. Human CD4+ T
cells were left unstimulated or were activated with anti-CD3 and anti-CD28 or anti-
CD46 as indicated, in the presence or absence of 1,25(OH)2D3. (A) Expression of
integrin b7 was determined by flow cytometry (representative of 4 donors, Vitamin
D=gray histograms, control=plain lines). Panel on the right shows the data obtainedFrontiers in Immunology | www.frontiersin.org 14for the 4 donors. (B) Expression of CCR9 and CCR10 was quantified by qPCR (n=5
donors, mean ± SEM, one way Anova with Sidak’s multiple comparisons test).
SUPPLEMENTARY FIGURE 4 | 1,25(OH)2D3 modulates expression of
adhesion molecules on MS CD4+ T cells. Human CD4+ T cells purified from the
blood of healthy donors (HC, Figure 1) and patients with RRMS (see Table 1) were
left unstimulated (US) or were activated with anti-CD3 and anti-CD28 or anti-CD46
as indicated, in the presence or absence of 1,25(OH)2D3. After 4 days, expression
of CD49d, CD11a, CD29, CD99, CD146, CD166, CD6 and CD226 was assessed
by flow cytometry (MS: mean ± SEM, n=17, Friedman test with Dunn’s multiple
comparison test and Kruskall-Wallis test).
SUPPLEMENTARY FIGURE 5 | The modulation of adhesion molecules by 1,25
(OH)2D3 is not affected by treatments. Human CD4+ T cells purified from the blood
of patients with RRMS (see Table 1) were left unstimulated (US) or were activated
with anti-CD3 and anti-CD28 or anti-CD46 as indicated, in the presence or absence
of 1,25(OH)2D3. After 4 days, expression of CD49d, CD29, CD6, CD146, CD166,
and CD226 was assessed by flow cytometry (UT=untreated; DMF=dimethyl
fumarate; IFNb=beta-interferon).
SUPPLEMENTARY FIGURE 6 | Effect of 1,25(OH)2D3 on CXCR3 expression.
CXCR3 expression on unstimulated, CD3, CD3/CD46 or CD3/CD28-co-activated
T cells from healthy donors in the presence or absence of 1,25(OH)2D3 (n=25,
mean ± SEM).
SUPPLEMENTARY FIGURE 7 | t-SNE clustering representation of the effects of
Vitamin D supplementation on T cells in patients with MS. (A) t-SNE representation
and (B) intensity of staining of CD46, CD25, CD162, CD45RA, CD127, CD146,
CD6, Foxp3 and CD226 in CD3+CD4+ T cell clusters of PMBCs from patients with
MS supplemented by vitamin D or placebo (n=5 and n=4, respectively).
SUPPLEMENTARY FIGURE 8 | 1,25(OH)2D3 induces PSGL-1 on CD46-
costimulated T cells. Human CD4+ T cells purified from the blood of healthy donors
were coactivated with anti-CD3 and anti-CD28 or anti-CD46 as indicated, in the
presence or absence of 1,25(OH)2D3. After 4 days, expression of PSGL-1/CD162
was assessed by flow cytometry (mean ± SEM, n=8, Friedman test with Dunn’s
multiple comparison test).
SUPPLEMENTARY FIGURE 9 | Vitamin D supplementation does not
specifically modulate the proportion of Tregs in patients with MS. (A) Identification of
the Treg clusters (Foxp3hiCD25hiCD127lo) by PhenoGraph analysis and their
phenotype (5 patients supplemented with vitamin D and 4 placebo (all IFNb treated).
(B) Percentage and count of these two Treg clusters in the vitamin D and placebo
groups before and after treatment.
SUPPLEMENTARY FIGURE 10 | Vitamin D supplementation modulates the
phenotype of T cells in patients with MS after in vitro activation. Percentage of the 19
CD3+CD4+ T cell clusters identified by PhenoGraph in the vitamin D and placebo
groups (n=3 and n=4, respectively) before and after treatment after CD28 or CD46
costimulation of PMBCs. Clusters increased (green boxes) or decreased (blue
boxes) after vitamin D supplementation are indicated.
SUPPLEMENTARY FIGURE 11 | CD46-costimulation represses TIGIT
expression on activated T cells. Human CD4+ T cells purified from the blood of
healthy donors were coactivated with anti-CD3 and anti-CD28 or anti-CD46 as
indicated, in the presence or absence of 1,25(OH)2D3. After 4 days, expression of
TIGIT was assessed by flow cytometry (mean ± SEM, n=5, Friedman test with
Dunn’s multiple comparison test).REFERENCES
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